PRVAPrivia Health Group, Inc.
Is the price fair?
The yardsticks disagree: cheap against its own 5-year P/E range (14th percentile) but the cash-flow math implies demanding growth. Treat as fair, not cheap.
Cheap vs its own history: P/E 99.3 vs a 136.6 median over 14 quarters (−27% vs median).
Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What PRVA's price assumes
Privia Health Group, Inc. trades at 99.3× earnings against 46.0× for the median Health Information Services name, more expensive than its own group.
Trailing P/E · Health Information Services median 46.0 · 2.16× the median: the market pays up for this one
- Price / sales
- 1.46
Price / sales · today's price, fiscal year to Dec 31, 2025
- Price / book
- 4.19
Price / book · today's price, fiscal year to Dec 31, 2025
- EV / sales
- 1.23
EV / sales
Details›
- Price / booktoday's price, fiscal year to Dec 31, 2025
- 4.19
- EV / EBIToperating margin 1.9%: the multiple describes the denominator
- not meaningful
- EV / salestoday's price, fiscal year to Dec 31, 2025
- 1.23
- Healthcare median P/E509 names
- 26.2
- Health Information Services median P/E25 names
- 46.0
- Market capitalisation
- $3.09B
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $24.83 |
| Its own P/E history, median | $28.68 |
| Its own P/E history, upper quartile | $38.80 |
| 52-week range | $19.11 – $28.09 |
| Today | $20.85 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Health Information Services
Ranks #14 of 20 by RyuScore